Home › Acute Biphenotypic Leukemia › Nevada › Las Vegas
Acute Biphenotypic Leukemia clinical trials in Las Vegas, NV
3 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around Las Vegas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
- Summerlin Hospital Medical Center, Las Vegas
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
- Summerlin Hospital Medical Center, Las Vegas
Acute Biphenotypic Leukemia trials in other cities
- Seattle, WA15 studies
- Houston, TX11 studies
- New York City, NY10 studies
- Atlanta, GA9 studies
- Durham, NC8 studies
- Chicago, IL7 studies
- Memphis, TN7 studies
- Aurora, CO6 studies
- Dallas, TX6 studies
- Philadelphia, PA6 studies
- Baldwin Park, CA6 studies
- Portland, OR6 studies
Other studies in Las Vegas
- Obesity27 studies
- Overweight23 studies
- Type 2 Diabetes18 studies
- Non-Small Cell Lung Cancer13 studies
- Major Depressive Disorder12 studies
- Breast Cancer10 studies
- Cancer (all types)9 studies
- Alzheimer's Disease8 studies
- Endometrial Cancer8 studies
- Acute Myeloid Leukemia8 studies
- Prostate Cancer8 studies
- Atherosclerosis7 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.